Dermal objective pharmacodynamic profile of cetirizine and epinastine: Two controlled randomised, double-blind, crossover studies

International Journal of Clinical Practice

Volumn 56, Issue 8, 2002, Pages 568-573

  Leroy, T ^a   Van Neste, Dominique ^a  

^a NONE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; EPINASTINE; HISTAMINE RECEPTOR; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN EXPERIMENT; LASER DOPPLER FLOWMETRY; MICROVASCULARIZATION; NERVE FIBER; NORMAL HUMAN; PRICK TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BLOOD FLOW; SKIN BLOOD VESSEL; SKIN TEST; TIME; URTICARIA; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; CETIRIZINE; CROSS-OVER STUDIES; DIBENZAZEPINES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ERYTHEMA; HISTAMINE H1 ANTAGONISTS; HUMANS; IMIDAZOLES; LASER-DOPPLER FLOWMETRY; SKIN; SKIN TESTS;

EID: 0036776030     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Adamus WS, Oldigs-Kerber J, Lohmann HF. Antihistamine activity and central effects of WAL 801 CL in man. Eur J Clin Pharmacol 1987; 33: 381-385.
2. Juhlin L, De Vos C, Rihoux JP. Inhibiting effect of cetirizine on histamine-induced and 48/80-induced wheals and flares, experimental dermographism, and cold-induced urticaria. J Allergy Clin Immunol 1987; 80: 599-602.
3. Juhlin L, Arendt C. Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. Br J Dermatol 1988; 119: 67-71.
4. Van Neste D. Skin response to histamine dry skin prick test: influence of duration of the skin prick on clinical parameters and on skin blood flow monitoring. J Dermatol Sci 1990; 1: 435-440.
5. Rihoux JP, Ghys L, Muhlethaler K, Wuthrich B. The skin as a target organ for the investigation of antiallergic drugs: comparison between cetirizine and terfenadine. Dermatology 1992; 184: 111-115.
6. Juhlin L. A comparison of the pharmacodynamics of H1-receptor antagonists as assessed by the induced wheal-and-flare model. Allergy 1995; 50: 24-30.
7. Grant JA, Danielson L, Rihoux JP, DeVos C. A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy 1999; 54: 700-777.
8. Lee EE, Maibach HI. Treatment of urticaria: an evidence-based evaluation of antihistamines. Am J Clin Dermatol 2001; 2: 27-32.
9. Trevino RJ, Veling MC. The importance of quantifying skin reactivity in treating allergic rhinitis with immunotherapy. Ear Nose Throat 2002; 79: 362-364, 366.
10. Serup J, Staberg B. Quantification of weal reactions with laser Doppler flowmetry: comparative blood flow measurements of the oedematous centre and the perilesional flare of skin-prick histamine weals. Allergy 1985; 40: 233-227.
11. Van Neste D. Skin Response to histamine: reproducibility study of the dry skin prick test method and of the evaluation of microvascular changes with laser Doppler flowmetry. Acta Derm Venereol (Stockh) 1991; 71: 25-28.
12. Coulson ML, Hayes NA, Foreman JC. Comparison of infrared and helium-neon lasers in the measurement of blood flow in human skin by the laser-Doppler technique. Skin Pharmacol 1992; 5: 81-86.
13. Hagermark O, Hokfelt T, Pernow B. Flare and itch induced by substance P in human skin. J Invest Dermatol 1978; 71: 233-225.
14. Jorizzo JL, Coutts AA, Eady RA, Greaves MW. Vascular responses of human skin to injection of substance P and mechanism of action. Eur J Pharmacol 1983; 87: 67-76.
15. Barnes PJ, Brown MJ, Dollery CT et al. Histamine is released from skin by substance P but does not act as the final vasodilator in the axon reflex. Br J Pharmacol 1986; 88: 741-745.
16. Petersen LJ, Church MK, Skov PS. Histamine is released in the wheal but not the flare following challenge of human skin in vivo: a microdialysis study. Clin Exp Allergy 1997; 27: 284-295.
17. Lewis T, Grant RT. Vascular reactions to injury. Heart 1924; 2: 209-265.
18. Bakker RA, Wieland K, Timmerman H, Leurs R. Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur J Pharmacol 2000; 387: R5-R7.
19. Ogiso T, Kasutani M, Tanaka H et al. Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles. Biol Pharm Bull 2001; 24: 790-774.
20. Poulsen LK, Bindsley-Jensen C, Rihoux JP. Quantitative determination of skin reactivity by two semiautomatic devices for skin prick test area measurements. Agents Actions 1994; 41: C134-C135.
21. Van Neste D, Rihoux JP. Inhibition of the cutaneous response to histamine by H1-blocking agents. Skin Pharmacol 1988; 1: 192-199.
22. Rihoux J-P, Van Neste D. Quantitative time course study of the skin response to histamine and the effect of H1 blockers. Dermatologica 1989; 179: 129-134.
23. Thysman S, Jadoul A, Leroy T et al. Laser Doppler evaluation of skin reaction in volunteers after histamine iontophoresis. J Control Release 1995; 36: 215-219.